Publications, Pharmaceutical

Why it is time to think differently about Nasal delivery of Biologics

COVID-19 has reinvigorated interest in the advantages of nasal delivery for a pharmaceutical industry already embracing a shift towards biologics.

This article considers the challenges and potential benefits of combining the two. The nasal delivery of biologics offers considerable potential for both local and systemic action and for direct access to the brain and CNS to address currently unmet therapeutic need. The unique features of biologics are discussed with reference to the associated difficulties of nasal delivery and the benefits of partnership with experts such as Aptar Pharma is highlighted. Work on the development of vaccines and prophylactics for COVID-19 illustrates what is achievable.

Download Publication
Author(s): Gemma Budd Irene Rossi
4 Apr 2022

Learn more about Aptar Pharma Expertise
in Nasal Drug Delivery

Find Out More About nasal drug delivery expertise

This Might Also Be of Interest

18 Nov 2021

Delivering On The Promises of Intranasal Vaccination

Publications, Pharmaceutical, Market Insights, Product Solutions, Device Innovations

Read More
2 Nov 2021

Successfully Balancing The Needs of The Planet With The Needs of The Patient

Publications, Pharmaceutical, Sustainability, Innovation & Insights, Device Innovations, Product Solutions

Read More
26 Oct 2021

Using digital healthcare to improve patient compliance and adherence

Webinars, Pharmaceutical, Brand Differentiation, Product Solutions, Innovation & Insights, Device Innovations

Read More
16 Sep 2021

Introducing PureHale® for targeted upper respiratory tract care

Webinars, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Read More
1 … 14 15 16 17 18 … 25

How Can We Help?

Back To Top